Full-Time

Junior/Mid Software Engineer

Mytos

Mytos

11-50 employees

Automated scalable human cell manufacturing platform

No salary listed

London, UK

Hybrid

Hybrid role; typically 2-3 days on-site per week.

Category
Software Engineering
Required Skills
Prisma
React.js
Node.js
Postgres
GraphQL
TypeScript

Get referred to Mytos

See people who can refer or advise you

Requirements
  • Are early in your software career and want to join an environment that gives you the chance to grow quickly
  • Have demonstrated technical promise so far in your studies or work
  • Want to work on difficult technical challenges in a field that will define the biggest scientific advancement this century
  • Self-starter attitude with a drive for producing quality work
  • Care and compassion for customers and colleagues
  • Experience with full-stack web development using TypeScript or other typed languages
  • Experience with modern frontend frameworks (React preferred)
  • Experience with backend development and API design (Node.js preferred)
  • Experience working with databases (PostgreSQL and Prisma or similar ORM experience ideal)
Responsibilities
  • Collaborate closely with other engineers to deliver end-to-end product functionality spanning experiment scheduling, automated image analysis, and remote operation of our devices
  • Develop and improve our frontend applications using TypeScript, React, and GraphQL to create intuitive interfaces for complex biological workflows
  • Build backend services that communicate with our hardware systems and learn about data integrity throughout the cell manufacturing process
  • Collaborate across disciplines with hardware engineers, biologists, and commercial teams to build reliable and effective systems in record time
  • Learn and contribute to our testing methods to help us deliver quality software at speed
  • Learn and contribute to architecture and infrastructure, system performance, and interesting distributed system challenges
  • Write code that you can immediately see the real-world impact: testing on our prototype machines in our own lab
  • Up-skill in domains outside software engineering, from donning a lab coat and be trained on the nuances of stem cells, to the basics of fluid mechanics
  • Be given a lot of autonomy, responsibility, and ownership of product problems and the technical solutions you design and deliver to address customer needs
Desired Qualifications
  • Understanding of distributed systems concepts
  • Experience with Python for data processing or image analysis
  • Background or interest in biology, lab automation, or scientific instrumentation
  • Any experience with regulated environments (GMP, HIPAA, etc.)
  • Any experience with UI/product design processes and tools (wireframes, mockups, looks-like prototypes, etc.)

Mytos.bio provides automated, end-to-end manufacturing for human cell types used in biotech. It sells and supports its proprietary Mytos Platform, which combines robotics and software to run cell culture processes without needing more staff. This turns traditional artisanal cell culture into scalable, repeatable production for large biotech firms working on cell therapies and drug development. The system works by integrating automated equipment and software workflows that manage culture, monitoring, and quality control, enabling consistent, high-quality cells at scale. Compared with competitors, Mytos.bio emphasizes a turnkey, scalable infrastructure that reduces headcount while delivering uniform results, backed by a team of hardware and software engineers and biologists, and recognition as a YCombinator alumnus and Forbes 30 Under 30. Its goal is to make large-scale cell production reliable and cost-effective so biopharma companies can accelerate therapies and drug development.

Company Size

11-50

Company Stage

Series A

Total Funding

$20.9M

Headquarters

London, United Kingdom

Founded

2016

Get referred to Mytos

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • October 2025 CDMO launch targets 1,500 autologous and 25,000 allogeneic doses annually.
  • CGT Catapult collaboration strengthens validation, regulatory trust, and manufacturing integration.
  • Adding Catalent and Cellares veterans improves quality systems and commercialization execution.

What critics are saying

  • Cellares dominates automated cell manufacturing with $350M funding and Bristol Myers Squibb backing.
  • Mytos raised only $19M Series A, limiting U.S. and Europe expansion.
  • September 2026 clinical readiness is a hard deadline; any delay hurts credibility fast.

What makes Mytos unique

  • Mytos iDEM automates familiar flask-based stem-cell workflows, lowering adoption friction.
  • September 2025 Stevenage CDMO gives Mytos controlled GMP capacity, not just software.
  • Partnerships with Aspen Neuroscience, StemSight, Rinri Therapeutics, and Novadip validate utility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options

Pension

Lunch covered daily

24 days holiday (excluding bank holidays)

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

0%
Yahoo Finance
Sep 3rd, 2025
Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials

Mytos announces strategic partnerships with StemSight, Rinri Therapeutics, and Novadip to power next-generation cell therapy trials.

Brown Brothers Media
Jan 8th, 2025
Mytos Announces Manufacturing Collaboration With Aspen Neuroscience In Parkinson'S Disease

Mytos’ automated cell culture technology will power manufacturing of dopaminergic neuronal precursor cells for Aspen’s investigational cell therapy ANPD001 in Parkinson’s diseaseLONDON–(BUSINESS WIRE)–#automation—Mytos, an innovative leader in automated cell manufacturing, has entered into a manufacturing collaboration with Aspen Neuroscience, Inc. to automate the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease (PD).The DANPCs, designed to replace lost dopamine-producing neurons in the brain, are differentiated from induced pluripotent stem cells (iPSCs), which are derived from the patient’s own skin cells. This approach holds the promise of restoring lost function without the need for immunosuppressive drugs.As part of the partnership agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing facility in Torrey Pines, Calif. The iDEM automated cell culture technology combines fluidics, advanced imaging, and mechanical movement and control to enable fully hands-off production of specific human cell types. This agreement represents the potential for substantial payments to Mytos over the coming years.Mytos’ automation has the potential to drive substantial improvements in efficiency and scalability. By closing and automating processes, iDEM empowers operators to manage more batches simultaneously within a smaller cleanroom footprint, minimizing the need for extensive hiring, training, and facility expansions as manufacturing scales out.“We are excited to work with the innovative Mytos team

PitchBook
Dec 1st, 2023
Global VC deals for December 1, 2023

Generative AI business automation startup Kognitos raised a $20 million Series A led by Khosla Ventures.

Manchester Times
Nov 30th, 2023
Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth

Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC.

U.S. Securities and Exchange Commission
Oct 12th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.